

Haematologica
HAEMATOL/2016/163436
Version 3

Combined targeting of STAT3 and STAT5: a novel approach to
overcome drug resistance in chronic myeloid leukemia

Karoline V. Gleixner, Mathias Schneeweiss, Gregor Eisenwort, Daniela Berger, Harald Herrmann, Katharina Blatt, Georg Greiner, Konstantin Byrgazov, Gregor Hoermann, Marina Konopleva, Islam Waliul, Abbarna A. Cumaraswamy, Patrick T. Gunning, Hiroshi Maeda, Richard Moriggl, Michael Deininger, Thomas Lion, Michael Andreeff, and Peter Valent

Disclosures: 1) This study was supported by Austrian Science Fund (FWF), grants F4701-B20 F4704-B20 (to P.V.), F4705-B20 (to T.L.) and F4707-B20 (to R.M.) and by a Grant-in-Aid from the Ministry of Welfare, Health and Labor of Japan, (201220042), and A-STEP for cancer grant (AS242Z01542Q) from the Japan Science and Technology Agency (to H.M.). 2) G.H.:Research Funding: Gilead; Honoraria: Novartis, Ariad, Amgen M.K.: Equity Ownership: Reata Pharmaceuticals Consultancy and Research Funding: Abbvie, Genentech, Stemline; Research Funding: Eli Lilly,Collectis, Calithera M.D.: Consultancy and Membership on an entity's Board of Directors or advisory committees: Ariad, Incyte; Consultancy and Research Funding: Bristol Myers Squibb; Membership on an entity's Board of Directors or advisory committees: CTI BioPharma Corp.; Research Funding: Gilead; Consultancy , Membership on an entity's Board of Directors or advisory committees and Research Funding: Novartis, Pfizer T.L.:Honoraria: Novartis, BMS, Pfizer, Ariad, Amgen; Research support: Novartis P.V.: Honoraria: Amgen Honoraria and Research Funding: Novartis, Celgene, Ariad; Pharmaceuticals Research; Funding: Deciphera All other authors have nothing to disclose. 3) There are no patents relevant to this work

Contributions: Karoline V. Gleixner: Performed cell culture, Contributed primary samples, Performed biologic assays, Planed the study, Analyzed the data, Wrote the draft Mathias Schneeweiss: Performed cell culture, Performed biologic assays, Performed flow cytometry Harald Herrmann: Performed flow cytometry Katharina Blatt: Performed flow cytometry, Performed biologic assays Daniela Berger: Conducted Western blot analysis Gregor Eisenwort: Performed FACS sorting of transfected cells Georg Greiner: Performed RNA-knock-down Konstantin Byrgazov: Generated and provided new cell lines Gregor Hoermann: Performed RNA-knock-down Marina Konopleva: Contributed novel drugs (CDDO-Me) Islam Waliul: Contributed novel drugs (SMA-ZnPP) Abbarna A. Cumaraswamy: Contributed novel drugs (AC-3-019) Patrick T. Gunning: Contributed novel drugs (AC-3-019) Hiroshi Maeda: Contributed novel drugs (SMA-ZnPP) Richard Moriggl:Contributed novel drugs (AC-3-019) Michael Deininger: Generated and provided new cell lines Thomas Lion: Generated and provided new cell lines Michael Andreeff: Contributed novel drugs (CDDO-Me) Peter Valent: Provided logistic and budget support, Approved the data and the final version of the manuscript